148 related articles for article (PubMed ID: 19578225)
1. Cost-effectiveness of supplementary immunization for measles in India.
Dabral M
Indian Pediatr; 2009 Nov; 46(11):957-62. PubMed ID: 19578225
[TBL] [Abstract][Full Text] [Related]
2. Incremental cost-effectiveness of supplementary immunization activities to prevent neonatal tetanus in Pakistan.
Griffiths UK; Wolfson LJ; Quddus A; Younus M; Hafiz RA
Bull World Health Organ; 2004 Sep; 82(9):643-51. PubMed ID: 15628201
[TBL] [Abstract][Full Text] [Related]
3. Measles epidemiology and outbreak response immunization in a rural community in Peru.
Sniadack DH; Moscoso B; Aguilar R; Heath J; Bellini W; Chiu MC
Bull World Health Organ; 1999; 77(7):545-52. PubMed ID: 10444877
[TBL] [Abstract][Full Text] [Related]
4. Measles control in Maputo, Mozambique, using a single dose of Schwarz vaccine at age 9 months.
Cutts FT; Monteiro O; Tabard P; Cliff J
Bull World Health Organ; 1994; 72(2):227-31. PubMed ID: 8205642
[TBL] [Abstract][Full Text] [Related]
5. Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa.
Uzicanin A; Zhou F; Eggers R; Webb E; Strebel P
Vaccine; 2004 Sep; 22(25-26):3419-26. PubMed ID: 15308367
[TBL] [Abstract][Full Text] [Related]
6. Widespread outbreaks of measles in rural Uttar Pradesh, India, 1996: high risk areas and groups.
Singh J; Kumar A; Rai RN; Khare S; Jain DC; Bhatia R; Datta KK
Indian Pediatr; 1999 Mar; 36(3):249-56. PubMed ID: 10713838
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.
Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z;
Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the benefits of increasing measles immunization rates.
Zwanziger J; Szilagyi PG; Kaul P
Health Serv Res; 2001 Oct; 36(5):885-909. PubMed ID: 11666109
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
Griffiths UK; Hutton G; Das Dores Pascoal E
Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
[TBL] [Abstract][Full Text] [Related]
10. Measles control in developing and developed countries: the case for a two-dose policy.
Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China.
Ding D; Kilgore PE; Clemens JD; Wei L; Zhi-Yi X
Bull World Health Organ; 2003; 81(5):334-42. PubMed ID: 12856051
[TBL] [Abstract][Full Text] [Related]
12. Two-dose measles vaccination schedules.
Rosenthal SR; Clements CJ
Bull World Health Organ; 1993; 71(3-4):421-8. PubMed ID: 8324862
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of alternative polio immunization policies in South Africa.
Griffiths UK; Botham L; Schoub BD
Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
[TBL] [Abstract][Full Text] [Related]
14. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
[TBL] [Abstract][Full Text] [Related]
15. Two doses of measles vaccine reduce measles dealths.
van den Ent M; Gupta SK; Hoekstra E
Indian Pediatr; 2009 Nov; 46(11):933-8. PubMed ID: 19955576
[TBL] [Abstract][Full Text] [Related]
16. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
[TBL] [Abstract][Full Text] [Related]
17. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
[TBL] [Abstract][Full Text] [Related]
18. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP.
Harris A; Hendrie D; Bower C; Payne J; de Klerk N; Stanley F
Med J Aust; 1994 Apr; 160(8):483-8. PubMed ID: 8170423
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation.
Platonov AE; Griffiths UK; Voeykova MV; Platonova OV; Shakhanina IL; Chistyakova GG; Robertson SE;
Vaccine; 2006 Mar; 24(13):2367-76. PubMed ID: 16413949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
